Agenda for November 2025 Pharmacology and Therapeutics Advisory Committee (PTAC) meeting
Information on what the Pharmacology and Therapeutics Advisory Committee (PTAC) will be considering at its upcoming meeting on 13 and 14 November 2025.
Applications
Nivolumab (branded as OPDIVO), for people with bladder cancer
The Committee will discuss an application for the funding of nivolumab with cisplatin chemotherapy for the first-line treatment of unresectable or metastatic urothelial carcinoma.
Application for nivolumab for people with bladder cancer(external link)
Semaglutide (branded as OZEMPIC) for people with type 2 diabetes
The Committee will discuss a new application for the funding of semaglutide for treatment of insufficiently controlled type 2 diabetes.
Application for semaglutide for people with type 2 diabetes(external link)
Anifrolumab (branded as SAPHNELO) for people with systemic lupus erythematosus (SLE)
The Committee will discuss a new application for the funding of anifrolumab for the treatment of severe systemic lupus erythematosus (SLE).
Application for anifrolumab for people with systemic lupus erythematosus (SLE)(external link)
Bevacizumab (branded as Vegzelma) for people with a blood vessel condition
The Committee will discuss two new applications for the funding of bevacizumab for severe hereditary haemorrhagic telangiectasia (HHT).
Application for bevacizumab for people with a blood vessel condition(external link)
Subcutaneous (SC) Pembrolizumab (branded as KEYTRUDA SC) for all funded indications where the intravenous formulation (IV) is funded
The Committee will discuss a new application for Subcutaneous pembrolizumab for use in the same conditions where intravenous Pembrolizumab is currently funded.
Subcutaneous Vedolizumab (branded as ENTYVIO) for people with the bowel diseases ulcerative colitis and Crohn’s disease
The Committee will discuss a new application for the funding of subcutaneous vedolizumab for the maintenance treatment of ulcerative colitis and Crohn’s disease.
Application for subcutaneous vedolizumab for ulcerative colitis and Crohn’s disease(external link)
Tezepelumab (branded as TEZSPIRE) for people with long term sinus inflammation and polyps
The Committee will discuss a new application for the funding of tezepelumab for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP).
Application for tezepelumab for people with long term sinus inflammation and polyps(external link)
Consideration of biosimilar tocilizumab
The Committee will discuss the evidence for transition from reference tocilizumab to biosimilar tocilizumab for intravenous and subcutaneous use.
Advisory meeting agenda setting
The scheduling and agenda setting process for advisory meetings considers multiple factors. We aim to balance the relative priorities of clinical advice needed across indications, the factors for consideration for each application (for example unmet health need), the time since applications were received and the internal and advisor resource available to support each meeting.